Device Trial Radar · NCT04374916
Evaluation of a New Predictive Test of Preterm Birth in Case of Threatened Preterm Labor
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Aug 11, 2020
Primary completion
Apr 4, 2025
Study completion Sep 2026
Sponsor
- Lead sponsor
- University Hospital, Strasbourg, FranceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 5, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Threatened preterm labor (TPL) is defined by cervical changes and regular and painful uterine contractions occurring between 24 and 36 + 6 weeks of gestation that may or may not lead to premature labor and delivery. There is no reliable way to predict preterm delivery. The study's hypothesis is that the Premaquick® test can improve the prediction of preterm delivery. The investigators also want to compare this test with the Partosure® (Placental alpha microglobulin-1) test.
Conditions
- Threatened Preterm Labor
- Preterm Delivery
Interventions
Premaquick®Device
Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
PARTOSURE®Device
An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcome measure will be the occurrence of a premature delivery within 7 days after patient's inclusion.Time frame: The outcome measure is assessed at visit 2 (day 7), 7 days after the inclusion visit.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpitaux Universitaires de Strasbourg
Strasbourg, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.